As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...

This week’s pre-holiday news roundup includes a Waltham biotech’s cardiometabolic collaboration with Novo Nordisk, Akari ...

The European Union's drug regulator said it would assess two new Danish studies that link Novo Nordisk's popular diabetes ...

A vision-threatening eye condition may be linked to Ozempic. Meanwhile, Nearly 80% of doctors are using telemedicine weekly, ...

Ozempic maker Novo Nordisk A/S is investing 8.5 billion kroner ($1.2 billion) to build a new major factory in Denmark to help ...

The maker of weight-loss and diabetes drugs has supercharged the Danish economy — but other businesses complain that’s left ...

Eli Lilly (LLY -1.28%) and Novo Nordisk (NVO 1.03%) have competed for decades. They're both leaders in the areas of insulin ...

Novo Nordisk's (NVO) acquisition of three Catalent (CTLT) production sites to close soon as its parent wins regulatory nod ...

The pharmaceutical company will establish a production facility in Odense to accommodate multiple product types within the ...

NVO's CagriSema target of up to 25% in long-term weight loss is highly promising vs. 15% through Wegovy and 20% through ...

STOCKHOLM (Reuters) -Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ($1.20 billion) in a new facility in Odense ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...